SOURCE-LINKED STUDY SUMMARY
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Full paper summarizedQuality not appraised
- What was studied
- A full-text phase 1 program tested the dual GIP/GLP-1 agonist LY3298176 in cells and mice, then in randomized, double-blind human studies against placebo; dulaglutide was an active control in healthy participants. Safety and tolerability were primary.
- Who / model studied
- A total of 142 people received LY3298176, placebo or dulaglutide: 56 in the single-dose study, 33 healthy participants in the four-week multiple-dose study and 53 people with type 2 diabetes in the proof-of-concept study.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- After four weeks, higher-dose groups with diabetes had lower fasting glucose versus placebo, and several healthy-participant groups lost more weight versus placebo. Gastrointestinal events were dose-dependent and mild to moderate; vomiting limited the single 8 mg dose.
- Limitations & context
- The trials were short and small, ethnic backgrounds differed between cohorts, dulaglutide was studied only in healthy participants, and the design could not separate GIP from GLP-1 contributions.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: full paper. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/j.molmet.2018.09.009